The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Computational Modelling To Understand Early-stage Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Rather than attempting to reverse neurodegeneration, therapeutic strategies must target the earliest possible stages of disease, when treatments have the potential to prevent or slow down pathological progression. The proposed project will employ computational modelling using functional MRI to deliver highly efficient and sensitive markers of Familial Alzheimer’s disease and Huntington’s disease progression to inform when in the progression of disease clinical trials should take place.
Biomarkers To Aid Clinical Trials For Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$13,179,875.00
Summary
Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effective drugs currently available. Whilst these diseases present with different symptoms, we’ve discovered that they share a common underlying feature; the inability to clear certain metals and proteins from the brain. Our program aims to explore these clearance pathways in the brain and identify new targets to help us better diagnose and treat these diseases.
Longitudinal Transcriptome Profiles For People With Dementia
Funder
National Health and Medical Research Council
Funding Amount
$475,913.00
Summary
Over the past decade, less than half a percent of drugs trialled for Alzheimer Disease were found to be effective. This highlights the need for new drug targets. This Fellowship aims to study how genes express themselves over time, among people with very high risk of dementia (genetic form of Alzheimer Disease and Huntington Disease). By looking at gene expression in nerve tissue in the nose, fluid around the brain, and blood, I hope to better understand the disease mechanisms causing dementia.
Development Of Blood-based Biomarkers For The Early Detection Of Brain Amyloid And The Investigation Of The Natural History Of Alzheimer’s Disease.
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
To have a direct impact on the diagnosis and treatment of Alzheimer’s and other neurodegenerative diseases we need a detailed molecular understanding of the proteins that drive the disease. My laboratory develops and applies the most advanced analytical tools available to develop blood-based markers that can detect the development of Alzheimer’s disease before symptoms occur. This Fellowship will allow me to expand our understanding of the natural history of Alzheimer’s disease.
DEVELOPMENT OF NOVEL THERAPEUTICS FOR DEMENTIA: Investigating Tailored Brain Stimulation Approaches For Dementia Prevention And Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$723,105.00
Summary
Dementia is a debilitating and devastating illness impacting significantly on sufferers, carers and the wider community. Current treatment approaches are limited in their effectiveness and alternative therapeutics are needed. My research will investigate the use of brain stimulation techniques for the treatment and prevention of dementia.
Early Detection Of Alzheimer's Disease Using Ocular Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$602,502.00
Summary
Curcumin fluorescence imaging of the retina will be tested for quantification of retinal amyloid plaque burden and rate of change. This will be compared to AD disease status, brain plaque burden and other markers to evaluate retinal imaging as an early test for AD.
Therapeutic And Diagnostic Approaches For The Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
Diseases of the brain such as Alzheimer’s and Parkinson’s disease cause enormous socio-economic harm to Australia. They are a major cause of disability and the burden associated with mental illness is predicted to grow by almost 50% over the coming decade. Therefore there is an urgent need to develop new approaches to identify and treat these diseases. This Fellowship will be dedicated to creating new diagnostic methods and treatments for these diseases
The Future In Our Hands: Screening For Preclinical Alzheimer's Disease By Analysing Hand Movements
Funder
National Health and Medical Research Council
Funding Amount
$899,782.00
Summary
Alzheimer's disease (AD) starts damaging the brain 10-20 years before memory problems begin. By the time of diagnosis, it is hard to treat because the damage is so severe. We need a way to detect AD much earlier. We will develop a simple new computer test to detect early signs of AD by recording and analysing hand movements. Then people can start prevention earlier and scientists can research better treatments to improve people's quality of life and reduce the number of people with dementia.
Genetic Investigations For Prodromal Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$719,374.00
Summary
The disease process in Alzheimer’s disease (AD) begins decades before a diagnosis is made. We urgently need to investigate this pre-symptomatic stage to learn how the disease process begins, and allow the development of treatments that work before the brain is irreparably damaged. I will use genetic risk factors for AD to predict who is most at risk of developing AD. I will look for early changes and easily accessible markers, including the use of state of the art brain imaging.
Element Labeling Antibodies For Bio-imaging Of Proteins: A Case Study Of Beta-amyloid In Alzheimer's Disease Mouse Models
Funder
National Health and Medical Research Council
Funding Amount
$221,136.00
Summary
This project will develop new analytical methods for quantitative in-situ imaging of beta-amyloid in mouse brains. Beta-amyloid deposition in the brain is associated with Alzheimer�s disease. It is also planned to simultaneously image metal ions, which are also implicated in the deposition of beta-amyloid. Application of these novel methods to Alzheimer�s disease mouse models will provide new knowledge and significant insights into the aetiology of Alzheimer�s disease by determining the relation ....This project will develop new analytical methods for quantitative in-situ imaging of beta-amyloid in mouse brains. Beta-amyloid deposition in the brain is associated with Alzheimer�s disease. It is also planned to simultaneously image metal ions, which are also implicated in the deposition of beta-amyloid. Application of these novel methods to Alzheimer�s disease mouse models will provide new knowledge and significant insights into the aetiology of Alzheimer�s disease by determining the relationship between amyloid proteins and metal ions.Read moreRead less